Home | Articles
Published on:February 2024
Indian Journal of Pharmaceutical Education and Research, 2024; 58(2):624-636
Original Article | doi:10.5530/ijper.58.2.70

Design, Synthesis, Anticancer Activities and Comparative Molecular Docking Studies of a Novel Class of 7-Azaindole Analogs as Potent PARP-1 Inhibitors


Authors and affiliation (s):

Neha Sharma1,*, Anurag Chaudhary2, Monika Sachdeva1

1Department of Pharmacy, Rajkumar Goel Institute of Technology (Pharmacy), NH-58, Ghaziabad, Uttar Pradesh, INDIA.

2Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, NH-58, Near Baghpat Crossing, Bypass Road, Meerut, Uttar Pradesh, INDIA.

Abstract:

Background: In a research facility, 7-azaindole derivatives were designed and synthesized, and each substance was examined for its capacity to inhibit cancer growth. In the present study, the synthesized analogues were docked with PARP enzyme to find a suitable site for PARP inhibition. Materials and Methods: 1H nuclear magnetic resonance, 13C NMR, and mass spectrometry were used to characterize all synthesized analogues of 7-azindole. On the MCF-7 cell line for breast cancer, their anticancer activity was assessed. The proteins of PARP-1 inhibitors were docked against using the protein IDs 6NRF, 6NRG, 6NRH, 6NRI, 6NRJ, and 6NTU. For 7-azaindole derivatives, the two docked proteins 6NRH and 6NRF performed best. Results: The most active compound against MCF-7 cell lines has a GI50 of 15.56 μM, which is compound 4g. The compounds 4a, 4b, 4c, 4i, and 4h also exhibited good anticancer activity so these compounds have the prospective to be used as PARP inhibitors. According to additional molecular docking studies these compounds can bind to protein targets 6NRH well. These compounds offer promising potential as PARP inhibitors for the development of novel medications. Conclusion: The results of the study were favorable and gave direction for the synthesis of some novel potent 7-Azaindole compounds as a PARP inhibitors.

Keywords: 7-azaindole, Synthesis, Docking, Anticancer activity, PARP inhibitor.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs